Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.

In addition, Emergent has secured new incremental orders with an international government partner valued at $6.6 million USD. This represents product orders for ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) within Emergent's medical countermeasures portfolio and will support the partner's smallpox biodefense strategy. These orders stem from a recurring international customer and demonstrate the importance of threat preparedness around the world.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.